Leila Pirhaji

ReviveMed, an MIT spinout, is an AI-driven metabolomics platform for precision medicine. Our patented technology detects 20x more metabolites per patient than traditional methods, enabling the creation of digital metabolic twins. Digital metabolic twins are virtual patient models representing individuals’ metabolic networks within a multi-omic context to simulate health and disease. We have a pipeline of metabolic twins for oncology and cardio-metabolic diseases, such as renal cell carcinoma, MASH, and obesity. Our metabolic twins increase trial success rates by predicting which patients respond to drugs and reducing trial sizes by simulating disease progression in placebo arms while providing mechanistic insights to prioritize and expand drug pipelines. We have several ongoing biopharma partnerships and have worked with 40% of the top-10 pharma.